HIV-1 drug resistance in French infected-children: from newborn to adolescent;La résistance du VIH-1 aux antirétroviraux chez les enfants infectés : du nouveau-né à l'adolescent

Archives de Pediatrie

Volumn 14, Issue 3, 2007, Pages 298-302

  Delaugerre, C ^a   Chaix, M L ^a   Warszawski, J ^b   Rouzioux, C ^a   Blanche, S ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b BICÊTRE HOSPITAL   (France)

Author keywords

Antiretroviral; Children; HIV; Newborn; Resistance

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ARTICLE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; TREATMENT FAILURE; VIRUS TRANSMISSION;

ADOLESCENT; ANTI-RETROVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; FRANCE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN;

EID: 33847369795     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcped.2006.12.007     Document Type: Article

References (14)

1. Tamalet C., Fantini J., Tourres C., et al. Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997-2002) based on an analysis of over 7000 genotypes. AIDS 17 (2003) 2383-2388
2. Richman D.D., Morton S.C., Wrin T., et al. The prevalence of antiretroviral drug resistance in the United-States. AIDS 18 (2004) 1393-1401
3. Mullen J., Leech S., O'Shea S., et al. Antiretroviral drug resistance among HIV-1 infected children failing treatment. J. Med. Virol. 68 (2002) 299-304
4. Machado E.S., Lambert J.S., Watson D.C., et al. Genotypic resistance and HIV-1 subtype in Brazilian children on dual and triple combination therapy. J. Clin. Virol. 30 (2004) 24-31
5. Robbins G.K., De Gruttola V., Shafer R.W., et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N. Engl. J. Med. 349 (2003) 2293-2303
6. Kempf D.J., King M.S., Bernstein B., et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J. Infect. Dis. 189 (2004) 51-60
7. Mellins C.A., Brackis-Cott E., Dolezal C., et al. The role of psychosocial and family factors in adherence to antiretroviral treatment in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. 23 (2004) 1035-1041
8. Anderson P.L., Kakuda T.N., Kawle S., et al. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS 17 (2003) 2159-2168
9. Fletcher C.V., Jiang H., Brundage R.C., et al. Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. J. Infect. Dis. 189 (2004) 1176-1184
10. Jullien V., Urien S., Hirt D., et al. Weight, age, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years: a population analysis. Antimicrob. Agents Chemother. (2005) (in press)
11. Masquelier B., Chaix M.L., Burgard M., et al. Zidovudine genotypic resistance in HIV-1-infected newborns in the French perinatal cohort. J. Acquir. Immune Defic. Syndr. 27 (2001) 99-104
12. Parker M.M., Wade N., Lloyd Jr. R.M., et al. Prevalence of genotypic drug resistance among a cohort of HIV-infected newborns. J. Acquir. Immune Defic. Syndr. 32 (2003) 292-297
13. Ghosn J., Pellegrin I., Goujard C., et al. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS 20 (2006) 159-170
14. Yeni P. Prise en charge des personnes infectées par le VIH. Recommandations du groupe d'experts (2006)